Have a personal or library account? Click to login
Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study Cover

Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study

Radiology and Oncology
Volume 56 (2022): Issue 3 (September 2022)
By: Nina Turnsek,  Rok Devjak,  Natalija Edelbaher,  Ilonka Osrajnik,  Mojca Unk,  Dusanka Vidovic,  Tina Jeric and  Urska Janzic  
Open Access
|Aug 2022
DOI: https://doi.org/10.2478/raon-2022-0025 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 371 - 379
Submitted on: Jan 31, 2022
|
Accepted on: Apr 7, 2022
|
Published on: Aug 14, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
real-world study,
non-small cell lung cancer,
epidermal growth factor receptor,
T790M testing,
attrition
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2022 Nina Turnsek, Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dusanka Vidovic, Tina Jeric, Urska Janzic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 56 (2022): Issue 3 (September 2022)Next article